[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"memory-impairment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:memory-impairment":540},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,54,85,98,127,152,175,199,229,269,291,330,355,378,392,414,449,485,510],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":35,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100053319",false,"NCT05663034","CBT-I vs. MBTI for Traumatic Brain Injury (TBI)-Related Insomnia and Post-Traumatic Stress Symptoms","CoMBat Insomnia: A Randomized Controlled Trial of Cognitive-Behavioral vs. Mindfulness-Based Treatment for TBI-Related Insomnia and Post-Traumatic Stress Symptoms","Inclusion Criteria:\n\n1. Current or former member of the uniform services\n2. Meet the Veterans Affairs Medical Center (VAMC) Department of Defense (DoD) criteria for TBI;\n3. Time duration since traumatic brain injury (TBI) injury \\>90 days\n4. Insomnia symptom duration \\>90 days\n5. Endorse insomnia symptoms (Insomnia Severity Index \\[ISI\\] score \\> 10)\n6. Display sufficient cognitive capacity to provide informed consent (Montreal Cognitive Assessment (MoCA) Z-score \\> -2)\n7. \\>18 years of age\n8. Access to and ability and to use computer.\n\nExclusion Criteria:\n\n1. History of neurological diseases other than TBI and not attributable to TBI\n2. Sleep apnea \\[apnea hypopnea index (AHI) \\>15; individuals with mild apnea (AHI \\> 5 and \\\u003C15) will be informed, but allowed to participate\\]. Participants who use a continuous positive airway pressure (CPAP) device for sleep apnea will be eligible for participation if they are below the apnea\u002Fhypopnea cutoff while using CPAP, are adherent to using the device (\\> 4 hours\u002Fnight 21\u002F30 consecutive days) and agree to continue using the device during study participation.\n3. Lastly, people using psychotropic medications may be included if they are on a stable dosage for the last three weeks prior to the study.","ALL","18 Years",{"count":18,"type":19},360,"ESTIMATED","INTERVENTIONAL",[22],"NA","This study is a prospective two-arm, single blind randomized controlled trial design to compare the clinical effectiveness of telemedicine-delivered, 6-session, standardized cognitive behavioral therapy for insomnia (CBT-I) and mindfulness-based treatment for insomnia (MBTI) in treating insomnia symptoms and ameliorating depressive symptoms in persons with mild to moderate TBI and comorbid Post-Traumatic Stress Symptoms (PTSS) and insomnia symptoms in a 360 patients. Participants will undergo assessment (psychosocial questionnaires, neurocognitive testing, sleep monitoring) at baseline, at the end of treatment, and at 2-, 6- and 12-weeks post-treatment. The primary outcome is sleep as measured by the Insomnia Severity Index (ISI).",[25,26,27,28,29,30,31,32,33,34],"Traumatic Brain Injury","Insomnia","Depression","Post-traumatic Stress","Sleep","Memory Impairment","Cognitive Behavioral Therapy","Concussion, Brain","Head Injury","Brain Injury Traumatic Mild",[25,26,36,27,37,33,38,39,40],"Posttraumatic Stress Symptoms","Concussion","Brain Injury","Cognitive Behavioral Therapy for Insomnia","Mindfulness-based Treatment for Insomnia","RECRUITING","2026-07-10",{"date":44,"type":45},"2026-07-13","ACTUAL",{"date":47,"type":45},"2024-05-10",{"date":49,"type":19},"2027-06",{"name":51,"class":52},"Johns Hopkins University","OTHER",5,{"id":55,"slug":4,"hasResults":10,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":15,"minAge":62,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":20,"phases":65,"briefSummary":67,"conditions":68,"keywords":71,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":78,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},"100053654","NCT04601038","Trial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X)","Phase II Trial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X)","CORT-X","Individuals must meet criteria for mild cognitive impairment due to Alzheimer's disease according to National Institute on Aging (NIA)\u002FAlzheimer's Association recommendations OR be cognitively normal based on clinical and cognitive assessment in the Enrollment Visit and have at least one of the following risk factors for AD:\n\n* Known to have at least 1 apolipoprotein E (APOE) ε4 allele;\n* Subjective cognitive concerns with a T score \\\u003C 40 on the Multifactorial Memory Questionnaire Satisfaction Scale;\n* A first-degree relative with dementia.\n\nInclusion Criteria for all subjects:\n\n* At least 55 years of age;\n* Body mass index \\>17 and \\\u003C30;\n* Post-menopausal (if female)\n* Non-smoker;\n* Availability of a study partner who has frequent contact with the subject (10+ hours\u002Fweek in person and by telephone), and is able to provide an independent evaluation of functioning;\n* Fluent English speaker;\n* Good general health with no disease expected to interfere with the study;\n* Willing and able to participate for the duration of the study.\n\nExclusion Criteria for all subjects:\n\n* Participation in a therapeutic clinical trial at any time during the study;\n* Abnormal corrected QT interval using Bazett's formula (QTcB; defined as \\> 450 ms for men and \\> 470 ms for women) as determined on ECG;\n* Any significant neurologic disease other than suspected incipient Alzheimer's disease, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic deficits or known structural brain abnormalities, including lacunes in critical memory structures including the hippocampus and parahippocampal cortex;\n* Bipolar disorder within the past 1 year;\n* History of alcohol or drug dependence;\n* Any significant systemic illness or unstable medical condition, which could lead to difficulty complying with the protocol;\n* General surgery within the last 3 months;\n* Sensory impairment (poor vision or hearing) significant enough to interfere with ability to provide valid cognitive test data;\n* Treatment within the last six months with neuroleptics, sedative hypnotics, or glucocorticoids;\n* Treatment within the last six months with medications metabolized by the CYP2C9 or CYP2C19 enzymes, most notably clopidogrel and proton pump inhibitors;\n* Concurrent use of a CYP3A inhibitor, including grapefruit juice, and St. John's Wort;\n* Exceptions to these guidelines may be considered on a case-by-case basis at the discretion of the PI.",true,"55 Years",{"count":64,"type":19},52,[66],"PHASE2","CORT-X will examine if mitigation of stress-mediated pathogenesis of Alzheimer's disease (AD) is a feasible target for intervention in individuals at risk for this disease. This single-site (Baltimore, Maryland) phase II clinical trial is a 2-week, randomized, placebo-controlled crossover study of the effects of the selective glucocorticoid receptor antagonist, CORT108297, on cognitive test performance in 26 individuals with mild cognitive impairment (MCI) due to AD and in 26 cognitively normal individuals with an increased risk for AD due to family history, genetics, and\u002For subjective memory complaints. All subjects will participate in a brief stressor (public speaking and mental arithmetic) and provide saliva samples so investigators can measure stress hormone response. Then, following 2 weeks of treatment with placebo or CORT108297, in counterbalanced order, participants will complete cognitive tests assessing memory and executive function. All study participants will receive CORT108297 and placebo over the course of this 10-week trial that requires 6 in-person study visits. The primary aims will compare the effects of CORT108297 to placebo on cognitive test performance in individuals with MCI due to AD and in individuals at risk for AD, and describe the side effects of CORT108297 in study participants. Secondary aims will identify subject characteristics that predict positive response to study drug.",[69,70,30],"Mild Cognitive Impairment","Alzheimer Disease",[72,73,74,75,76,77],"Stress","Memory loss","Dementia","Alzheimer's disease","Cognitive","Impairment",{"date":44,"type":45},{"date":80,"type":45},"2021-06-28",{"date":82,"type":19},"2028-01-01",{"name":51,"class":52},1,{"id":86,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":20,"phases":88,"briefSummary":23,"conditions":89,"keywords":90,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":95,"leadSponsor":97,"locationsCount":53},"100490200",{"count":18,"type":19},[22],[25,26,27,28,29,30,31,32,33,34],[25,26,36,27,37,33,38,39,40],"2026-05-26",{"date":93,"type":45},"2026-05-28",{"date":47,"type":45},{"date":96,"type":19},"2026-09",{"name":51,"class":52},{"id":99,"slug":4,"hasResults":10,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":61,"sex":15,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":20,"phases":108,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":84},"100473460","NCT05445180","Investigating the Neural Correlates of Cognitive Function in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use","Investigating the Neural Correlates of Cognitive Function Associated With Cannabis Abstinence in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use","Inclusion Criteria:\n\n* Able to provide informed consent in English or French\n* Heavy cannabis use (defined as weekly cannabis use for at six months) and\u002For DSM-5 diagnosis of CUD\n* Have a Full-Scale IQ ≥ 75\n* Meet DSM-5 criteria for a psychotic disorder (psychosis patient arm only)\n* Be an outpatient receiving a stable dose of medication(s) for at least two months (psychosis patient arm only)\n* Clinically stable (as measured by the PANSS-6, total score \\\u003C30) (psychosis patient arm only)\n\nExclusion Criteria:\n\n* current SUD (other than CUD)\n* MRI contraindications\n* Positive urine screen for psychoactive substances other than cannabis, nicotine, or caffeine\n* Current suicidal or homicidal ideation\n* Head injury requiring hospitalization or loss of consciousness \\> 5 minutes\n* Current medical diseases that requires hospitalization or regular monitoring\n* Being pregnant\n* DSM-5 Axis 1 diagnosis (other than CUD) (non-psychiatric controls only)\n* Taking psychotropic medication","16 Years","80 Years",{"count":107,"type":19},134,[22],"Cognitive impairment is well established in people with psychosis and is associated with cannabis use. The current study will investigate the neurobiological basis of cognitive change associated with 28-days of cannabis abstinence in people with psychosis and non-psychiatric controls with cannabis use. Participants will be randomized to a cannabis abstinent group or a non-abstinent control group and will undergo magnetic resonance imaging at baseline and following 28-days of abstinence. This study will help characterize the neuropathophysiological processes underlying cognitive dysfunction associated with cannabis use and its recovery which may guide the development of novel interventions for problematic cannabis use.",[111,112,113,114,115,116,30,117],"Psychotic Disorders","Cannabis Use Disorder","Cannabis Dependence","Cannabis Use","Schizophrenia; Psychosis","Cognitive Dysfunction","Neuroimaging","2026-05-19",{"date":120,"type":45},"2026-05-22",{"date":122,"type":45},"2022-04-21",{"date":124,"type":19},"2027-05",{"name":126,"class":52},"Douglas Mental Health University Institute",{"id":128,"slug":4,"hasResults":10,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":61,"sex":15,"minAge":134,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":20,"phases":137,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":84},"100506654","NCT05877196","A SMART Trial of Adaptive Exercises to Optimize Aerobic-Fitness Responses","Precision Medicine in Alzheimer's Disease: A SMART Trial of Adaptive Exercises and Their Mechanisms of Action Using AT(N) Biomarkers to Optimize Aerobic-Fitness Responses (The FIT-AD SMART Trial)","SMART","Inclusion Criteria:\n\nParticipants:\n\n* Clinical diagnosis of MCI or probable and possible mild AD dementia according to 2011 Alzheimer's association-NIA criteria.\n* Community-dwelling, e.g., homes and assisted living\n* Age 65 years and older\n* Medical clearance from PCP or cardiovascular provider\n* Have a qualified study partner\n* Agree to the blood draws\n* Verified MRI safety\n\nStudy Partner:\n\n* Age 18 or older\n* Contact with participant ≥ 2 times per week for ≥ 6 months\n* Know the participant's memory status and ability to perform activities of daily living\n* Consent to participant\n\nExclusion Criteria:\n\nParticipants\n\n* Resting HR ≤ 50 or ≥ 100 beats\u002Fmin after 5-minutes of quiet resting\n* American College of Sports Medicine contraindications to exercise\n* New, unevaluated symptoms or diseases a healthcare provider has not evaluated\n* Abnormal cardiac condition uncovered during VO2peak testing\n* Enrollment in another intervention that aims at improving cognition\n* Moderate to strenuous exercise ≥150 minutes a week in the previous 6 months\n* ≥ 2 anti-depression medications, or poorly managed or unstable depression\n* Poorly managed or unstable anxiety\n\nStudy partners:\n\n* none","65 Years",{"count":136,"type":19},216,[22],"The goal of this clinical trial is to test 6 months of aerobic exercise in older adults who are 65 years or older and have mild cognitive impairment (MCI) or probable\u002Fpossible mild Alzheimer's Disease. The main questions it aims to answer are:\n\n* test the effects of aerobic exercise on aerobic fitness, white matter hyperintensity (WMH) volume, and patient-centered outcomes;\n* identify the best exercise to improve aerobic fitness and reduce non-responses over 6 months; and\n* examines the mechanisms of aerobic exercise's action on memory in older adults with early AD.\n\nParticipants will receive 6 months of supervised exercise, undergo cognitive data collection and exercise testing 5 times over a year span, have an MRI brain scan 3 times over a one-year span, and have monthly follow-up discussions on health and wellness.",[69,70,140,141,142,30],"Cognitive Impairment","Cognitive Decline","Memory Loss","2026-05-01",{"date":145,"type":45},"2026-05-05",{"date":147,"type":45},"2023-06-22",{"date":149,"type":19},"2028-06-30",{"name":151,"class":52},"Arizona State University",{"id":153,"slug":4,"hasResults":10,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":10,"sex":15,"minAge":62,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":20,"phases":161,"briefSummary":162,"conditions":163,"keywords":164,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":84},"100477293","NCT05495087","IHT for Mild Cognitive Impairment","Intermittent Hypoxia Training: A Novel Therapy for Mild Cognitive Impairment","Inclusion Criteria:\n\n* Adult men and women ages 55 to 79 years old who have been diagnosed with MCI.\n* Must be willing to be assigned to either group: treatment or sham-treatment control.\n* Able to pay multiple visits to the lab for the proposed assessments.\n* Able to breathe moderately hypoxic air via an air-cushioned, disposable facemask.\n* To have controlled stabilized chronic conditions of at least 6 months duration, such as hypertension, coronary artery disease, diabetes or metabolic disease, chronic bronchitis, degenerative osteoporosis or arthritis and\u002For other aging-related chronic conditions.\n* Must be depression-free at the time of enrollment.\n* Must have arterial oxygen saturation at or above 95% and cerebral tissue oxygenation at or above 50% at rest.\n* Woman subject must be post-menopausal.\n\nExclusion Criteria:\n\n* Unwilling to sign a written consent to participate in this double-blinded placebo-controlled phase I trial.\n* Diagnosed with AD-dementia or have impaired independent daily functioning; with MMSE \\\u003C20 and\u002For CDR ≥1.\n* Unable to visit the lab independently.\n* Claustrophobic to facemask and hyper-reactive to hypoxia exposure.\n* Expecting any major surgery or transplant.\n* Have un-controlled chronic conditions including systolic-diastolic pressures over 150\u002F90 mmHg with medications, diabetes, chronic renal failure (based on the medical history questionnaire), recurrent chest pain, seizures or epilepsies, moderate to severe carotid stenosis or calcification, brain aneurysm, uncontrolled allergic rhinitis, pulmonary fibrosis, emphysema, cancer, infectious disease, atrial fibrillation, regular pre-mature ventricular contractions, myocardial ischemia or infarct, 2nd or 3rd degree atrio-ventricular blockade.\n* Have severe head injury or traumatic brain injury, stroke (hemorrhagic and\u002For ischemic).\n* Have currently diagnosed depression.\n* Currently have COVID-19.\n* Have any metallic implants or who are claustrophobic.\n* Currently participating in any interventional study and\u002For have been previously exposed to hypoxia, such as residing more than two months at altitudes above 5000 ft. within the past 3 years or previously participated in a hypoxia training study.","79 Years",{"count":160,"type":19},66,[22],"This phase I clinical trial will examine the safety and efficacy of intermittent hypoxia training (IHT) for up to 12 weeks to treat subjects with mild cognitive impairment (MCI).",[69,30],[165],"intermittent hypoxia training or preconditioning","2026-04-23",{"date":168,"type":45},"2026-04-29",{"date":170,"type":45},"2023-02-27",{"date":172,"type":19},"2026-04-30",{"name":174,"class":52},"University of North Texas Health Science Center",{"id":176,"slug":4,"hasResults":10,"nctId":177,"briefTitle":178,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":61,"sex":15,"minAge":134,"maxAge":105,"enrollmentInfo":180,"targetDuration":4,"studyType":20,"phases":182,"briefSummary":183,"conditions":184,"keywords":187,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":84},"100354562","NCT03896529","Neurobiological Mechanisms of Aging and Stress on Prospective Navigation","Inclusion Criteria:\n\n* adults 65-80\n* U.S. citizens or permanent residents\n* who speak fluent English\n* willing to come to Georgia Tech to participate in group testing sessions.\n\nExclusion Criteria:\n\n* Individuals will be carefully screened using IRB-approved procedures for safety contraindications to MRI and electrical shock stimulation\n* (e.g., metal or electrical implants, heart arrhythmia, or medication affecting the cardiovascular system \\[e.g. beta-blockers\\]).\n\nThe purpose of this study is to investigate mechanisms of normally functioning memory, and memory-related changes in healthy aging. Thus, any confounding factors that may influence cognition, other than age, will be exclusionary. Potential participants that endorse any of the following conditions will be excluded from the study:\n\n* Epilepsy\n* Dementia\n* Parkinson's disease\n* history of stroke or seizure\n* psychiatric disorders\n* untreated depression or emotional conditions\n* Attention Deficit Disorder\n* Multiple Sclerosis\n* uncontrolled hyper- or hypo-tension\n* untreated Diabetes\n* Sickle Cell Anemia\n* regularly use illegal or psychoactive drugs (e.g., cocaine, alcohol abuse, etc).\n* Additionally, individuals scoring \\\u003C 3 on WAIS-R forward span, \\\u003C 2 on WAIS-R backward span, and failing to name more than 2 vegetable names will be excluded from the study. These exclusions will insure that persons with mild cognitive impairment or typical indications of clinical dementia will be not participate in the research.",{"count":181,"type":19},85,[22],"Two hallmarks of both healthy aging and age-related disease are 1) memory and navigational deficits, particularly in orienting towards goal locations and planning how to navigate to them, and 2) increased susceptibility to stress and altered regulation of the stress response. However, there are marked individual differences in these age-related changes. The investigators' proposal will help characterize factors that contribute to this variability.\n\nParticipants will be pseudorandomly assigned to stress-manipulated or control groups. The investigators will give both groups a novel immersive navigation task, validated by the PI in healthy young adults. This paradigm gives participants the opportunity to either (a) flexibly draw on spatial memory in order to plan efficient routes to goal locations, or (b) fall back on inefficient, but cognitively less-demanding, stimulus-response associations (i.e., habits). Using neuroimaging and behavioral measures, the investigators' protocol will test whether experimentally-induced stress leads individuals to bring fewer details about future locations to mind when route planning, and whether such restricted prospective thought ultimately biases participants towards relatively inflexible, habitual actions.",[185,186,30],"Aging","Anxiety",[185,188,72,189],"Spatial Memory","fMRI","2026-04-16",{"date":192,"type":45},"2026-04-17",{"date":194,"type":45},"2019-09-24",{"date":196,"type":19},"2026-09-01",{"name":198,"class":52},"Georgia Institute of Technology",{"id":200,"slug":4,"hasResults":10,"nctId":201,"briefTitle":202,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":61,"sex":15,"minAge":205,"maxAge":206,"enrollmentInfo":207,"targetDuration":4,"studyType":209,"phases":4,"briefSummary":210,"conditions":211,"keywords":215,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":228},"100560992","NCT06584357","Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia","Bio-Hermes-002","Inclusion Criteria:\n\nPre-screening Inclusion Criteria\n\nParticipants must meet ALL of the following criteria to progress to Visit 1 (Screening):\n\n1. Participant is between 60 to 90 years of age (inclusive) at the time of consent; and\n2. Participant has a study partner who has sufficient and frequent contact with the participant (defined as at least 8 hours of contact a week) and is able to provide accurate information regarding the participant's cognitive and functional abilities.\n\nCore Study Inclusion Criteria\n\nParticipants must meet ALL of the following criteria, in addition to the Pre-screening Inclusion Criteria, for entry into the study:\n\n1. Participants must provide written consent in the IRB-approved or Ethics Committee (EC) approved informed consent form or have a legally authorized representative (LAR) provide written consent on the participant's behalf in accordance with local and national guidance and regulation;\n2. Participants must be willing to undergo an MRI brain scan within 90 days and an amyloid and tau PET scan within 120 days of signing informed consent;\n3. Participants must be willing to comply with all study procedures as outlined in the informed consent, including blood sampling, genetic testing, and storage of biospecimens for future research;\n4. Fluency in the language of the tests used at the study site;\n5. Participants must be willing to be contacted for possible participation in clinical research trials once their participation in this study ends; and\n6. Participants must have a Mini-Mental State Exam (MMSE) score of 16 to 30 inclusive at screening.\n\nExclusion Criteria:\n\nPre-screening Exclusion Criteria\n\nParticipants who meet ANY of the following criteria will not be eligible to progress to Visit 1 (Screening):\n\n1. Participant is unable to undergo amyloid and tau PET scans due to self-reported pregnancy, sensitivity to ligands being used, poor venous access, contraindication to PET, or planned or recent exposure to ionizing radiation that in combination with the planned administration of amyloid radioligand would result in a cumulative exposure that exceeds recommended local guidelines;\n2. Participants who have reported or have a known negative amyloid PET scan in the past 6 months;\n3. Participants with any known contraindication to brain MRI scan;\n4. Participants with history of stroke or seizures within 1 year of the Pre-Screening Visit;\n5. Participants with history of cancer within the past 5 years with the exception of non-melanoma skin cancer or prostate cancer in situ;\n6. Participants with known or suspected alcohol or drug abuse or dependence within 1 year of the Pre- Screening Visit;\n7. Participants who report any current unstable psychiatric symptoms that could interfere with study procedures or impact study data (e.g., uncontrolled depression);\n8. Participants who have received any potential disease modifying AD treatment within 6 months prior to the Pre-screening Visit; and\n9. Participants with known history or self-report to be Human Immunodeficiency Virus (HIV) Positive unless controlled by antiviral medication.\n\nCore Study Exclusion Criteria\n\nParticipants who meet ANY of the following criteria, in addition to the Pre-screening Exclusion Criteria, will not be eligible to enroll into the study:\n\n1. Participants who, in the opinion of the Site Principal Investigator, have serious or unstable medical conditions that would prohibit their completion of all study procedures and data collection;\n2. Participants who have serious or unstable medical conditions that would likely preclude their participation in an interventional research trial;\n3. Participants with self-reported, untreated conditions such as vitamin B12 or folate deficiency or bladder infections that in the opinion of the Site Principal Investigator could contribute to cognitive impairment;\n4. Participants who have completed cognitive testing within 1 month of Visit 1 (Screening) where the Site Principal Investigator believes the participant's exposure may cause practice effect;\n5. Participants who have any neurological disorder affecting the central nervous system, other than AD, that may be contributing to cognitive impairment (e.g., Parkinson's disease, other dementias, multiple concussions or seizures) as deemed significant by the Site Principal Investigator;\n6. Participants with a Geriatric Depression Scale (GDS) score greater than or equal to 8 at Visit 1 (Screening) and is deemed to be clinically significantly depressed by the Site Principal Investigator;\n7. Participants with a Rey Auditory Verbal Learning Test (RAVLT) t-score of ≥ 1.2 standard deviation above the mean. For non-African Americans, calculate age-sex-education adjusted t-scores. For African American participants, use the MOANS to calculate the age-education adjusted t-scores;\n8. Participants weighing less than 110 pounds;\n9. Participants who are direct employees or family members of direct employees of the participating investigators' sites;\n10. Participants who are direct employees of the Sponsor;\n11. Participants who, in the opinion of the investigator, are unable to complete cognitive testing due to inadequate visual or auditory acuity; and\n12. For participants completing the RetiSpec retinal scan: Those with a known history of contraindication or allergy to Tropicamide 1% (pupil dilation drop).\n\nLongitudinal Sub-Study Eligibility\n\nInclusion Criteria:\n\nParticipants must meet ALL of the following criteria for entry into the sub-study:\n\n1. Participants who completed the Bio-Hermes-002 Core Study;\n2. Are willing to complete phone call visits with site staff every three months and return to the clinic for an annual evaluation; and\n3. Are willing to complete annual PET scans for both amyloid and tau scans.\n\nExclusion Criteria:\n\nParticipants who meet ANY of the following criteria will not be eligible for entry into the sub-study:\n\n1. Those who are enrolled or intend to enroll into a clinical trial for Alzheimer's disease with a potential disease-modifying intervention;\n2. Participants who have serious or unstable medical conditions that would likely preclude their participation in an interventional research trial;\n3. Those who intend to use medications outside clinical research studies approved by regulatory authorities to modify Alzheimer's disease pathology.","60 Years","90 Years",{"count":208,"type":19},1200,"OBSERVATIONAL","Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective. Digital biomarkers and blood-based biomarkers will be tested to determine whether a meaningful relationship exists between biomarkers alone or in combination with tau or amyloid brain pathology identified through PET images.",[69,212,213,142,214,30],"Alzheimer's Disease","Alzheimer's Disease, Early Onset","Memory Disorders",[212,213,69,216,217,142,214,30],"Older Volunteers","Healthy Volunteers","2026-04-13",{"date":220,"type":45},"2026-04-15",{"date":222,"type":45},"2024-09-26",{"date":224,"type":19},"2028-07",{"name":226,"class":227},"GAP Innovations, PBC","INDUSTRY",26,{"id":230,"slug":4,"hasResults":10,"nctId":231,"briefTitle":232,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":20,"phases":237,"briefSummary":238,"conditions":239,"keywords":249,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":84},"100587627","NCT06930846","HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)","HOBSCOTCH-CA","CA Participants will be referred to the study by their providers (Oncologist) who will be made aware of the study and inclusion\u002Fexclusion criteria. Inclusion Criteria 2. - 5. and Exclusion Criteria 1. - 3. will be confirmed by referring providers. Participants who learn about the study here and elsewhere will be instructed on how to confirm their eligibility with their provider.\n\nInclusion Criteria for CA Participant:\n\n1. 18 + years\n2. Service members, Veterans and civilians with a diagnosis of brain cancer (excluding glioblastoma)\n3. Diagnosis of primary brain tumor with expected survival of 2 years or greater (e.g., low-grade glioma, oligodendroglioma, IDH mutant astrocytoma, meningioma) defined as the presence of a primary lesion on neuroimaging (CT or MRI), confirmed by histopathological examination (Note: some patients being treated for meningioma may be treated with radiotherapy without need for initial histopathologic confirmation)\n4. Patients undergoing surgical and\u002For radiation therapy will have completed their treatment at least 3 months prior to being enrolled in trial (Note: patients receiving chemotherapy or other systemic therapy will be included)\n5. Stable on all CNS acting medications for one month prior to enrollment\n6. Subjective cognitive complaints\n7. Literate and proficient in English\n8. Internet access for the pre-session and Session 1 of the HOBSCOTCH-CA program; telephone access for sessions 2-8\n\nExclusion Criteria for CA Participant:\n\n1. Presence of a neurodegenerative disease (e.g., Alzheimer's disease, Parkinson's disease)\n2. Acute psychiatric disorder or substance abuse\n3. Patients with glioblastoma (GBM)\n\nInclusion Criteria for CA Participant Caregiver:\n\n1. Age 18 +\n2. Caregiver to a patient with a confirmed diagnosis of brain cancer\u002Ftumor survivor\n3. CA Subject has given permission for their caregiver to participate\n4. Literate and proficient in English\n5. Internet access (for Pre-HOBSCOTCH and Session 1)\n6. Telephone access (for Session 8)\n\nExclusion Criteria for CA Participant Caregiver:\n\n1. Significant visual impairment precluding reading or writing\n2. No reliable telephone or internet access",{"count":236,"type":19},125,[22],"The purpose of this study is to assess the ability of the home-based intervention, HOBSCOTCH-CA, to improve the quality of life and cognitive function in Service Members, Veterans and civilians who are survivors of brain cancer or a brain tumor (CA participants). This study will also assess the ability of the HOBSCOTCH-CA program to improve quality of life in caregivers of patients with brain cancer\u002Ftumor and to reduce caregiver burden. Enrolling with a Caregiver is optional for CA participants.\n\nInvestigators will compare two groups of CA participants and their Caregiver (enrolling with a Caregiver is optional): one who receives HOBSCOCTCH-CA immediately (Group 1) and another group that will receive HOBSCOTCH-CA (Group 2) after a 3-month waiting period. Participants will be in the study for about 6 months total.\n\nHOBSCOTCH-CA involves 45 to 60 minute one on one virtual sessions with a certified Cognitive Coach including a \"pre\" program session and 8 weekly sessions thereafter. Participants will learn about problem solving therapy and mindfulness or relaxation training. CA participants are asked to do short homework assignments and keep a brief daily diary on a smart phone app. All participants complete study questionnaires or surveys at enrollment, 3 months later and at 6 months (at the end of the study).",[240,241,242,243,244,245,246,247,116,30,214,248],"Brain Cancer","Brain Tumor","Brain Neoplasms","Primary Brain Tumor","Low-grade Glioma","Oligodendroglioma","Meningioma","Low Grade Astrocytoma","Memory Dysfunction",[250,251,252,253,254,255,256,257,258,259],"Brain cancer survivor","Brain tumor survivor","Cognition","Self-management","Cognitive training","Memory disorders","Cognitive remediation","Caregiver","Caregiver burden","Mindfulness","2025-11-18",{"date":262,"type":45},"2025-11-21",{"date":264,"type":45},"2025-11-03",{"date":266,"type":19},"2028-12",{"name":268,"class":52},"Dartmouth-Hitchcock Medical Center",{"id":270,"slug":4,"hasResults":10,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":61,"sex":15,"minAge":275,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":20,"phases":278,"briefSummary":279,"conditions":280,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":84},"100515061","NCT05986604","NIA_Improving Function and Well-being by Improving Patient Memory: Transdiagnostic Sleep and Circadian Treatment","NIA_Improving Sleep and Circadian Functioning, Daytime Functioning, and Well-being for Midlife and Older Adults by Improving Patient Memory for a Transdiagnostic Sleep and Circadian Treatment","Inclusion criteria:\n\n1. Aged 50 years and older;\n2. English language fluency;\n3. Experiencing a mobility impairment;\n4. Low income;\n5. Exhibit a sleep or circadian disturbance as determined by endorsing 4 \"quite a bit\" or 5 \"very much\" (or the equivalent for reverse scored items) on one or more PROMIS-SD questions.\n6. 25-30 on the Montreal Cognitive Assessment, as a negative screen for cognitive impairment.\n7. Able\u002Fwilling to give informed consent.\n\nExclusion criteria:\n\n1. Severe untreated sleep disordered breathing (AHI\\>30) or moderate untreated sleep disordered breathing with severe daytime sleepiness (AHI of 15-30 and Epworth Sleepiness Scale \\>10);\n2. Medical conditions that prevent a participant from comprehending and following the basic tenants of treatment (e.g., dementia) or that interfere with sleep in a manner that can't be addressed by a cognitive behavioral treatment (e.g., the Structured Clinical Interview for Sleep Disorders will be used to screen for narcolepsy, REM sleep behavior disorder) or that may preclude full participation (e.g., receipt of end of life care);\n3. Homelessness;\n4. Night shift work \\>2 nights per week in the past 3 months;\n5. Substance abuse\u002Fdependence only if it makes participation in the study unfeasible;\n6. Suicide risk sufficient to preclude treatment on an outpatient basis.","50 Years",{"count":277,"type":19},178,[22],"Mental illness is often chronic, severe, and difficult to treat. Though there has been significant progress towards establishing effective and efficient interventions for psychological health problems, many individuals do not gain lasting benefits from these treatments. The Memory Support Intervention (MSI) was developed utilizing existing findings from the cognitive science literature to improve treatment outcomes. In this study, the investigators aim to conduct an open trial that includes individuals 50 years and older to assess if a novel version of the Memory Support Intervention improves sleep and circadian functioning, reduces functional impairment, and improves patient memory for treatment.",[281,282,30],"Sleep Disorder","Circadian Dysregulation",{"date":284,"type":45},"2025-11-24",{"date":286,"type":45},"2024-01-04",{"date":288,"type":19},"2028-07-28",{"name":290,"class":52},"University of California, Berkeley",{"id":292,"slug":4,"hasResults":10,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":296,"eligibilityCriteria":297,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":205,"enrollmentInfo":298,"targetDuration":4,"studyType":20,"phases":300,"briefSummary":301,"conditions":302,"keywords":312,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":329},"100547838","NCT06413173","Remotely Supervised tDCS+ for Complex Attention in mTBI (Cognetric)","Remotely Supervised tDCS Combined With Cognitive Training to Improve Complex Attention in Active Duty Service Members and Veterans With Mild TBI (Cognetric)","COGNETRIC","Inclusion Criteria:\n\n1. Active-Duty Service Members.\n2. Ages 18 to 60.\n3. All genders.\n4. All racial and ethnic groups.\n5. History of mild TBI (as defined by the DOD\u002FVA criteria used in conjunction with the OSU TBI-ID) sustained at least 3 months and no more than 10 years prior to enrollment.\n6. Self-reported attention and\u002For concentration difficulties.\n7. At least one cognitive symptom reported on the Neurobehavioral Symptom Inventory (NSI) cognitive subscale.\n\nExclusion Criteria:\n\n1. Presence of a medical, psychiatric, physical or non-physical disease, disorder, condition, injury, disability or pre-existent history such that study participation, in the opinion of the PI: (a) may pose a significant risk to the participant; (b) raises the possibility that the participant is unlikely to successfully complete all of the requirements of the study according to the study protocol; or (c) might adversely impact the integrity of the data or the validity of the study results. Specific conditions include (but are not limited to) a history of: brain tumor, epilepsy, cerebral vascular accident (CVA), Schizophrenia, Bipolar Disorder, and Mania.\n2. History of prior treatment with ECT or neuromodulation in the last 12 months.\n3. Current, diagnosed substance dependence.\n4. Newly prescribed medication within the previous 3 weeks.\n5. Diagnosis of intellectual disability or pervasive developmental disorder (i.e., premorbid IQ less than or equal to 70).\n6. Any medical condition or treatment other than mild TBI (e.g., stroke, tumor, HIV, moderate-severe TBI), with significant neurological disorder or insults that, based on the Principal Investigator's judgment, would impact risk.\n7. Psychosis or mania within 30 days of enrollment, as determined by the PI, based on a psychiatric history and examination and\u002For a review of available medical records\n8. Contraindications for tDCS (e.g., metallic cranial plates\u002Fscrews or implanted device, eczema or skin lesions on scalp)\n9. A positive pregnancy report.",{"count":299,"type":19},160,[22],"The proposed study will evaluate a new approach to cognitive rehabilitation of mTBI using a brain stimulation technique called \"Remotely Supervised Transcranial Direct Current Stimulation combined with Cognitive Training\" (RS-tDCS+) which has shown promise for improving complex attention in both healthy and clinical populations. RS-tDCS+ is a home-based, low-risk, non-invasive technique that is designed to boost cognitive training by enhancing learning and the brain's ability to reorganize connections. This study will evaluate RS-tDCS+ for improving complex attention in Active Duty Service Members (ADSM) and Veterans with a history of mTBI. Different tests of complex attention and symptom questionnaires will be used to determine the effects of real versus sham (placebo) RS-tDCS+. Second, the investigators will investigate electrical and connectivity changes in the brain associated with RS-tDCS+ using electroencephalogram (EEG) and magnetic resonance imaging (MRI). Third, the investigators will investigate the lasting effects of any observed changes by evaluating participants at 1 and 6 weeks post-treatment. Lastly, the investigators will explore the impact of individual differences (e.g., PTSD, depression, sleep quality, time since injury, baseline impairment, age, sex, ADSM versus Veteran) on treatment outcome.",[303,304,305,306,307,308,309,30,310,69,311],"Brain Concussion","Brain Trauma","Attention Concentration Difficulty","Brain Injuries","Brain Injuries, Traumatic","Neurocognitive Dysfunction","Attention Impaired","Mild Traumatic Brain Injury","Post Concussive Symptoms",[313,314,315,316,317,318],"Military Health","Brain Stimulation","Cognitive Training","Cognitive Rehabilitation","Telehealth","Neuromodulation","2025-11-07",{"date":321,"type":45},"2025-11-12",{"date":323,"type":45},"2024-07-25",{"date":325,"type":19},"2028-09-30",{"name":327,"class":328},"United States Naval Medical Center, San Diego","FED",2,{"id":331,"slug":4,"hasResults":10,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":10,"sex":15,"minAge":336,"maxAge":337,"enrollmentInfo":338,"targetDuration":4,"studyType":20,"phases":339,"briefSummary":340,"conditions":341,"keywords":343,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":354,"locationsCount":84},"100589246","NCT06951919","HOBSCOTCH-MS-Efficacy Trial","HOme-Based Self-management and COgnitive Training CHanges Lives (HOBSCOTCH) - Multiple Sclerosis (MS) - Efficacy Trial","Inclusion Criteria:\n\n* Inclusion Criteria - MS Participant\n\n  * Age 20 - 75 years\n  * Diagnosis of relapsing or progressive MS\n  * Education of at least Grade 12 or GED\n  * Fluent in English\n  * Subjective cognitive and memory challenges\n  * Internet access\n  * Telephone access\n\nInclusion Criteria - Caregiver Participant\n\n* 20 years +\n* Fluent in English\n* Caregiver to a MS Participant\n* Participant MS has given permission to Caregiver to enroll with them\n* Internet access\n* Telephone access\n\nExclusion Criteria:\n\n* Exclusion Criteria MS Participant\n\n  * Current diagnosed psychiatric disorders (e.g., schizophrenia, bipolar disorder or substance use disorder).\n  * Other neurological disorder such as epilepsy, brain tumor, severe brain injury or mild to moderate brain injury with a history of 30 or more minutes' loss of consciousness, or other disorder that would confound the focus on MS\n  * Diagnosed developmental attention, learning, or intellectual disorder; sensory, motor, or physical disability that would prevent engagement with the intervention or render the person unable complete study outcome measures\n  * Exacerbation of MS symptoms (relapse) or ongoing steroid treatment within three months of study enrollment\n  * Significant visual impairment precluding reading or writing\n  * Lack of access to the technical resources (e.g., internet access, telephone) required for participation\n\nExclusion Criteria - Caregiver Participant\n\n* Significant visual impairment precluding reading or writing\n* No reliable telephone or internet access","20 Years","75 Years",{"count":236,"type":19},[22],"The purpose of this study is to assess the ability of the home-based intervention, HOBSCOTCH-MS to improve the quality of life and cognitive function in Service Members, Veterans and civilians who have multiple sclerosis with cognitive and memory problems (MS participants). This study will also assess the ability of the HOBSCOTCH-MS program to improve quality of life in caregivers of patients with multiple sclerosis and to reduce caregiver burden. Enrolling with a Caregiver is optional for MS participants.\n\nInvestigators will compare two groups of MS participants and their Caregiver (enrolling with a Caregiver is optional): one who receives HOBSCOTCH-MS immediately (Group 1) and another group that will receive HOBSCOTCH-MS (Group 2) after a 3-month waiting period. Participants will be in the study for about 6 months total.\n\nHOBSCOTCH-MS involves 45 to 60 minute one on one virtual sessions with a certified Cognitive Coach including a \"pre\" program session and 8 weekly sessions thereafter. Participants will learn about problem solving therapy and mindfulness or relaxation training. MS participants are asked to do short homework assignments and both MS and Caregiver participants are asked to keep a brief daily diary on a smart phone app. All participants complete study questionnaires or surveys at enrollment, 3 months later and at 6 months (at the end of the study).\n\nAfter completing the intervention, MS Participants and their Caregivers may also participate in an optional one-time Key Informant Interview for qualitative analysis in an effort to further adapt and improve the HOBSCOTCH-MS in the future.",[342,116,214,30,248],"Multiple Sclerosis",[252,344,345,315,214,346,347,259],"Self-Management","Cognitive Remediation","Caregivers","Caregiver Burden","2025-10-27",{"date":350,"type":45},"2025-10-29",{"date":352,"type":45},"2025-09-09",{"date":266,"type":19},{"name":268,"class":52},{"id":356,"slug":4,"hasResults":10,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":360,"eligibilityCriteria":361,"healthyVolunteers":61,"sex":15,"minAge":62,"maxAge":4,"enrollmentInfo":362,"targetDuration":364,"studyType":209,"phases":4,"briefSummary":365,"conditions":366,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":84},"100602025","NCT07118137","Memory Deterioration in Alzheimer Disease","Translational Neuroscience CAG for Alzheimer's Disease","MemAD","Inclusion Criteria:\n\n* Confirmed diagnosis based on current ICD criteria for AD or MCI .\n* \\>55years.\n* Norwegian native speaker\n* Lives at home and not in a health institution\n\nExclusion Criteria:\n\n* Patients with severe cognitive impairment that prevents assessment with the selected modalities (planned cut-off: CDR \\> 2).\n* Presence of brain tumors.\n* History of traumatic brain injury.\n* History of cranial surgery.\n* Contraindications to the selected imaging modalities (e.g., 7T MRI or EEG).\n* Diagnosis of other neurodegenerative diseases such as Parkinson's disease or ALS.\n\n  7T MRI contraindications:\n* Large tattoos close to the head region, permanent makeup or unremoveable piercings\n* Certain models of pacemakers (if pacemaker implantet, MRI physicist at 7T-lab will be conferred)\n* Implantet metal in body (clips, stents, prothesis, skrews, plates, teeth etc.)",{"count":363,"type":19},30,"1 Year","Semantic AD",[70,367,368,30],"Neurodegenerative Diseases","Magnetic Resonance Imaging","2025-08-04",{"date":371,"type":45},"2025-08-12",{"date":373,"type":45},"2023-10-15",{"date":375,"type":19},"2027-12-31",{"name":377,"class":52},"Norwegian University of Science and Technology",{"id":379,"slug":4,"hasResults":10,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":380,"healthyVolunteers":61,"sex":15,"minAge":62,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":20,"phases":382,"briefSummary":67,"conditions":383,"keywords":384,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":389,"leadSponsor":391,"locationsCount":84},"100408635","Individuals must meet criteria for mild cognitive impairment due to Alzheimer's disease according to National Institute on Aging (NIA)\u002FAlzheimer's Association recommendations OR be cognitively normal based on clinical and cognitive assessment in the Enrollment Visit and have at least one of the following risk factors for AD:\n\n* Known to have at least 1 apolipoprotein E (APOE) ε4 allele;\n* Subjective cognitive concerns with a T score \\\u003C 40 on the Multifactorial Memory Questionnaire Satisfaction Scale;\n* A first-degree relative with dementia.\n\nInclusion Criteria for all subjects:\n\n* At least 55 years of age;\n* Body mass index \\>17 and \\\u003C30;\n* Post-menopausal (if female)\n* Non-smoker;\n* Availability of a study partner who has frequent contact with the subject (10+ hours\u002Fweek in person and by telephone), and is able to provide an independent evaluation of functioning;\n* Native English speaker;\n* Good general health with no disease expected to interfere with the study;\n* Willing and able to participate for the duration of the study.\n\nExclusion Criteria for all subjects:\n\n* Participation in a therapeutic clinical trial at any time during the study;\n* Abnormal corrected QT interval using Bazett's formula (QTcB; defined as \\> 450 ms for men and \\> 470 ms for women) as determined on ECG;\n* Any significant neurologic disease other than suspected incipient Alzheimer's disease, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic deficits or known structural brain abnormalities, including lacunes in critical memory structures including the hippocampus and parahippocampal cortex;\n* Major depression, bipolar disorder within the past 1 year;\n* History of alcohol or drug dependence;\n* Any significant systemic illness or unstable medical condition, which could lead to difficulty complying with the protocol;\n* General surgery within the last 3 months;\n* Sensory impairment (poor vision or hearing) significant enough to interfere with ability to provide valid cognitive test data;\n* Treatment within the last six months with antidepressants, neuroleptics, sedative hypnotics, or glucocorticoids;\n* Treatment within the last six months with medications metabolized by the CYP2C9 or CYP2C19 enzymes, most notably clopidogrel and proton pump inhibitors;\n* Concurrent use of a CYP3A inhibitor, including grapefruit juice, and St. John's Wort;\n* Exceptions to these guidelines may be considered on a case-by-case basis at the discretion of the PI.",{"count":64,"type":19},[66],[69,70,30],[72,73,74,75,76,77],"2025-07-18",{"date":387,"type":45},"2025-07-23",{"date":80,"type":45},{"date":390,"type":19},"2027-01-01",{"name":51,"class":52},{"id":393,"slug":4,"hasResults":10,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":397,"eligibilityCriteria":398,"healthyVolunteers":61,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":399,"targetDuration":4,"studyType":20,"phases":401,"briefSummary":402,"conditions":403,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":84},"100411882","NCT04643327","Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease","Double-blind Randomised-controlled Within-subject Crossover Trial to Determine Levetiracetam Efficacy for Memory Impairment in Parkinson's Disease: A Proof-of-concept Study","TRIP","Inclusion Criteria:\n\n* Parkinson's Disease patients with amnestic Mild Cognitive Impairment\n* Parkinson's Disease patients with no memory impairment\n* Healthy volunteers\n* All participants must be eligible to take MRI scans\n\nExclusion Criteria:\n\n* Dementia\n* Contraindication to having MRI\n* Bipolar disorder, Schizophrenia, Alcohol or substance abuse\n* Major depression\n* Suicidal Ideation\n* Difficulty complying with protocol requirements\n* Significant non-PD neurological disease\n* Vascular dementia\n* Sensitivity to levetiracetam\n* Use of anticonvulsant medications\n* Use of other excluded medications\n* Severe renal impairment\n* Clinically significant abnormalities in B12 or thyroid function test (below normative range for elderly)\n* Females of childbearing potential",{"count":400,"type":19},28,[66],"The present study is a proof-of-concept clinical trial to test the efficacy of low doses of a repurposed anti-epileptic drug (levetiracetam) in treating memory problems in Parkinson's disease (PD). Neuroimaging techniques will be used to determine the effect of the drug on specific brain regions (hippocampal subfields). Finally, baseline brain activity of PD patients with memory problems will be compared to PD patients without memory problems and healthy older adults to determine if activity in specific brain regions (hippocampal subfields) can be used to predict memory problems in PD. This information will be useful for future clinical trials to target drugs to these brain regions.",[404,69,30],"Parkinson Disease","2024-09-23",{"date":407,"type":45},"2024-09-25",{"date":409,"type":45},"2021-02-09",{"date":411,"type":19},"2025-12",{"name":413,"class":52},"The University of Queensland",{"id":415,"slug":4,"hasResults":10,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":4,"eligibilityCriteria":419,"healthyVolunteers":61,"sex":15,"minAge":275,"maxAge":420,"enrollmentInfo":421,"targetDuration":4,"studyType":20,"phases":423,"briefSummary":424,"conditions":425,"keywords":431,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":84},"100525638","NCT06124339","Brain Health Virtual Reality Study","Interventions to Promote Brain Health Virtual Reality Study","Inclusion Criteria:\n\n1. 50-85 years of age\n2. Fluent in English\n3. Can safely ride a stationary bike\n\nExclusion Criteria:\n\n1. Dementia\n2. History of a neurological disorder\n3. Severe sensory deficits\n4. Inability to perform intervention (e.g., inability to cycle safely)\n5. Contraindications to MRI scan (e.g., pacemaker)\n6. Fear of needles\u002F blood\n7. Prior history of fainting due to sight of needles of blood","85 Years",{"count":422,"type":19},150,[22],"The Interventions for Brain Health Virtual Reality Study is a NIH-funded clinical research trial at the University of California San Diego (UCSD) Health under the supervision of the study principal investigator Dr. Judy Pa. The overarching goal of this trial is to use a novel virtual reality (VR) based intervention that simultaneously engages physical and cognitive activity aimed at improving brain health and cognition in older adults. The investigators will compare 3 types of interventions: physical activity, VR cognitive activity, and combined VR physical and cognitive activity over 16 weeks to evaluate physical and brain health changes.",[185,426,142,30,427,428,214,69,141,429,430],"Aging Problems","Memory Disorders in Old Age","Memory Disorder, Spatial","Cognitive Change","Cognition Disorders in Old Age",[432,433,434,435,436,437,438,439],"Virtual Reality","technology","intervention","exercise","cycling","memory","brain health","aging","2024-07-08",{"date":442,"type":45},"2024-07-10",{"date":444,"type":45},"2023-08-08",{"date":446,"type":19},"2029-02-01",{"name":448,"class":52},"University of California, San Diego",{"id":450,"slug":4,"hasResults":10,"nctId":451,"briefTitle":452,"officialTitle":452,"acronym":453,"eligibilityCriteria":454,"healthyVolunteers":10,"sex":15,"minAge":455,"maxAge":4,"enrollmentInfo":456,"targetDuration":4,"studyType":20,"phases":458,"briefSummary":459,"conditions":460,"keywords":464,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":476,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":329},"100520029","NCT06051240","Lithium Treatment to Prevent Cognitive Impairment After Brain Radiotherapy","LiBRA","Inclusion Criteria:\n\n* Age \\>5 years.\n* Age \\\u003C18 years at time of radiotherapy.\n* Has received cranial\u002Fcraniospinal radiation treatment of brain tumor within the last 7 years.\n* Adequate contraceptive method to prevent pregnancy\\* during the entire lithium treatment period and six months thereafter.\n* Negative pregnancy test\\* at screening, at start of study treatment, and monthly thereafter.\n* Written informed consent from patient and\u002For caregiver.\n\nExclusion Criteria:\n\n* Allergy\u002Fhypersensitivity to lithium or any of the excipients\n* Renal failure (Cystatin C derived Glomerular Filtration Rate \\\u003C 60).\n* Cardiac failure or heart disease, including Brugada syndrome (or family history thereof).\n* Uncontrolled hypothyroidism.\n* Pregnancy or breast feeding.\n* Severe fluid or electrolyte imbalance.\n* Karnofsky-Lansky score \\\u003C 60.\n* Other condition deemed incompatible with inclusion in this study (estimated 2 year survival prognosis less than 25 %, expected poor protocol compliance, inability to swallow tablets, language difficulties).\n* Inclusion in other study protocol precluding inclusion in this study.","5 Years",{"count":457,"type":19},84,[66],"Randomized, placebo-controlled, double-blinded, parallel group clinical trial to investigate if 6 months of oral lithium tablets (S-lithium 0,5-1,0 mmol\u002Fl) will prevent cognitive decline after brain radiotherapy in pediatric brain tumor survivors.\n\nPrimary outcome measure is Processing Speed Index (PSI) 2 years after start of study treatment.",[140,141,461,462,241,30,463],"Radiotherapy Side Effect","Radiotherapy; Complications","Late Effect of Radiation",[465,466,467,468,469,470,471,472,473,474],"lithium","neuroprotection","neuroprotective","regenerative","prevention","radiation","pediatric brain tumor","brain tumor","cognition","cognitive","2024-04-11",{"date":477,"type":45},"2024-04-12",{"date":479,"type":45},"2024-02-16",{"date":481,"type":19},"2033-08-31",{"name":483,"class":484},"Region Stockholm","OTHER_GOV",{"id":486,"slug":4,"hasResults":10,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":490,"eligibilityCriteria":491,"healthyVolunteers":10,"sex":15,"minAge":134,"maxAge":4,"enrollmentInfo":492,"targetDuration":4,"studyType":20,"phases":494,"briefSummary":495,"conditions":496,"keywords":497,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":508,"locationsCount":329},"100232347","NCT02302482","Predictive Factors and Autonomy Level Change","Predictive Factors of the Autonomy Level Change Related to Memory Disorders","MEMORA","Inclusion Criteria:\n\n* Patients who undergo a medical visit in the Memory Clinic for the 1st time\n* Patients living at home or in housing\n* Patients with memory impairment, at all stage of the disease\n\nExclusion Criteria:\n\n* Patients in institution\n* Patients under legal protection\n* Patients with a hearing or visual impairment, which dot not allow to carry out the examination",{"count":493,"type":19},10860,[22],"The Alzheimer's disease or related disorders (ADRD) are among the most disabling diseases because of their main features such as cognitive impairment, loss of functional autonomy and behavioural disorders. In absence of current curative treatment, the identification of the predictive risk factors of progression of the disease, evaluated through its main symptoms, represents a major stake of public health. The investigators aimed at developing a database, which includes the patient medical records on a prospective basis, in collaboration with the medical and administrative personal and with the University hospital computer science department. The main objective is to study the predictive factors associated with the change of functional autonomy level, measured every 6 months to 12 months by phone, in a Memory Clinic. The study population would consist in about 1000 patients with ADRD. The length of follow-up of each patient will be 3 years.",[30],[498,499,500,501],"Alzheimer's disease or related disorders","Functional autonomy level","Cognitive function","Predictive factors","2021-06-25",{"date":80,"type":45},{"date":505,"type":45},"2014-11",{"date":507,"type":19},"2027-11",{"name":509,"class":52},"Hospices Civils de Lyon",{"id":511,"slug":4,"hasResults":10,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":4,"eligibilityCriteria":515,"healthyVolunteers":61,"sex":15,"minAge":516,"maxAge":16,"enrollmentInfo":517,"targetDuration":4,"studyType":209,"phases":4,"briefSummary":519,"conditions":520,"keywords":524,"overallStatus":530,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":4},"100366720","NCT04054934","Influence of Circadian Clock on Hormonal, Metabolic, Neurocognitive Markers in Adolescents With and Without Diabetes","Influence of Circadian Clock on Diurnal Dietary Intake, Glucose Variability, Time Spent in Range, and Neuro-cognitive Achievements Among Adolescents With and Without Type 1 Diabetes","Inclusion Criteria:\n\n* Families living in areas with high access to medical care.\n* Age: 12-18 years old\n* T1D diagnosis for longer than 1 year\n* speaking fluent Hebrew\n\nExclusion Criteria:\n\n* significant renal or liver function abnormalities\n* head injuries,\n* epileptic episodes\n* psychiatric medications\n* lack of Hebrew abilities\n* disagreement to comply with all the study requests\n* history of more than one episode of a severe hypoglycemic event in the past, including loss of consciousness or more than one episode of diabetic ketoacidosis.","12 Years",{"count":518,"type":19},100,"Type 1 diabetes mellitus (T1DM), makes its appearance during childhood and youth, but management implications last till late adulthood. Its treatment includes the combination of multiple daily glucose measurements, insulin administration and balanced nutrition. The goals of therapy are to achieve glycemic control (HbA1c \\\u003C 7.5%), and minimal glycemic excursions. Furthermore, recent studies imply that keeping HbA1c within target range is not sufficient to prevent complications, attributed mainly to blood glucose level fluctuating from high to low, associated with food intake and adolescents behavior. The current implication of glycemic control on the central nervous system (CNS) includes abnormal electrical brain activity, structural changes in brain's white and grey matter, and cognitive impairment. Still, little is known on the effect of sleep pattern, including circadian rhythm reversal (\"biological clock) on asymptomatic glycemic excursions, and on CNS functions. There is no data regarding the association of the biologic clock on CNS functionality among adolescents, nonetheless among T1DM adolescents, for whom behavior and circadian rhythm alterations may have harmful effect. The investigators propose a cross-over designed study by examining adolescents with and without T1DM during 2 weeks of regular sleeping pattern (night sleep), and during 2 weeks of sleeping during the day as happens during summer vacation. The main objective of the proposed study is to offer proof of the clinical and metabolic relevance and cognitive effects of the reversal of the circadian clock in adolescents with and T1DM during summer vacations and weekends. Study is designed to demonstrate a difference among healthy and diabetics during reversed night\u002Fday circadian clocks in the time spent within target range of glucose, performance on neuro cognitive tasks, electrical brain activity, and hormonal profile.",[521,522,523,30],"T1DM","Sleep Disorders, Circadian Rhythm","ADHD",[521,525,526,527,528,529],"Hypothalamus","CORTICAL BRAIN","Glucose variability","Biological clock","Pediatrics","NOT_YET_RECRUITING","2020-05-22",{"date":533,"type":45},"2020-05-26",{"date":535,"type":19},"2022-01",{"date":537,"type":19},"2026-12",{"name":539,"class":484},"Assaf-Harofeh Medical Center",""]